You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Chartwell Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for CHARTWELL, and what generic and branded alternatives to CHARTWELL drugs are available?

CHARTWELL has five hundred and seventy-nine approved drugs.

There are three tentative approvals on CHARTWELL drugs.

Summary for Chartwell

US Patents:	0
Tradenames:	386
Ingredients:	362
NDAs:	579

Drugs and US Patents for Chartwell

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	LOVASTATIN	lovastatin	TABLET;ORAL	075300-003	Dec 17, 2001	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Chartwell Rx	DICLOFENAC SODIUM	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	074394-001	Nov 30, 1995		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Chartwell Rx	CEFUROXIME AXETIL	cefuroxime axetil	TABLET;ORAL	065166-002	Jul 29, 2005	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Chartwell Rx	DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE	atropine sulfate; diphenoxylate hydrochloride	TABLET;ORAL	207128-001	Oct 21, 2020	AA	RX	No	No		⤷ Sign Up				⤷ Sign Up
Chartwell Rx	ALFUZOSIN HYDROCHLORIDE	alfuzosin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079056-001	Jul 18, 2011		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Chartwell Molecular	TEMOZOLOMIDE	temozolomide	CAPSULE;ORAL	203898-001	Feb 10, 2016		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Chartwell Rx	PHENTERMINE HYDROCHLORIDE	phentermine hydrochloride	TABLET;ORAL	088596-001	Apr 4, 1984		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Chartwell

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chartwell Molecular	MYKROX	metolazone	TABLET;ORAL	019532-001	Oct 30, 1987	4,517,179	⤷ Sign Up
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-004	Approved Prior to Jan 1, 1982	3,491,093	⤷ Sign Up
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-005	Approved Prior to Jan 1, 1982	3,491,093	⤷ Sign Up
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-008	Approved Prior to Jan 1, 1982	3,491,093	⤷ Sign Up
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-007	Approved Prior to Jan 1, 1982	3,491,093	⤷ Sign Up
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-006	Approved Prior to Jan 1, 1982	3,491,093	⤷ Sign Up
Chartwell Rx	LIMBITROL DS	amitriptyline hydrochloride; chlordiazepoxide	TABLET;ORAL	016949-002	Approved Prior to Jan 1, 1982	4,316,897	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.